Overview

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs. Data will be collected from each eligible participant initiating tocilizumab treatment over 6 months.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Antirheumatic Agents